BioBright and Philips Collaborate on New AI to Improve the Patient and Clinician Experience

BOSTON–(BUSINESS WIRE)–BioBright, a data and analytics company unlocking the potential of unstructured clinical and research information, today announced an agreement with Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, to develop information solutions that improve the patient and clinician experience across the healthcare continuum. This development collaboration follows the participation of BioBright in the Philips HealthWorks Startup Program in Cambridge, MA.

Today’s healthcare systems are focused on the quadruple aim: supporting population health in the communities they serve, reducing costs, and improving the patient and clinician experience. Successful systems continually strive to increase data usability, streamline workflows, and find new ways to capture and deliver important clinical insights in pursuit of these aims. By combining leading-edge Philips solutions and over a century of healthcare insights with BioBright’s secure voice and data processing technologies, clinicians will have the ability to quickly input and access the patient information they need to make informed care decisions.

Providing access to data sources in a secure manner that respects patient privacy is still a challenge in healthcare today,” said Charles Fracchia, CEO and founder of BioBright. “Working with a market leader like Philips allows us to better understand these complexities and how we can naturally integrate ambient information into the clinical data environment. This lets us reduce administrative burdens and cognitive demands while putting the patient back at the center of healthcare.”

Advances in technology have forced clinicians to spend more time on data entry, toggling between disparate systems and chasing down studies instead of focusing on the patient,” said Alberto Prado, Head of Philips HealthWorks. “Our Philips HealthWorks startup program allows us to collaborate with promising young companies like BioBright and find ways to break down data silos, integrating and processing large volumes of data from multiple sources regardless of vendor. We can then present this data back in a manner that makes sense for the clinician, allowing them to get back to basics and giving them more time for human interaction with their patients.”

BioBright is a privately owned data and analytics company in Boston, MA, where it began operations in 2015. BioBright’s technology enables biomedical companies to securely and privately collect and analyze data at scale. Initially funded by DARPA, the company is now deploying with leading equipment manufacturers and biomedical companies, including four on the Fortune 500 list.

Contacts

Charles Fracchia

BioBright

press@biobright.com

+1 (617) 444-9007

Staff

Recent Posts

Financière de Tubize – Annual report 2023

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: investorrelations@financiere-tubize.be Annual Report…

16 hours ago

ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP…

16 hours ago

Ibogaine By David Dardashti Leverages Albert Einstein’s Corelation Between Photon Particles and Quantum Electrodynamics

Ibogaine By David Dardashti Revolutionizes Solar Energy Efficiency Through Radiation Generators Einstein A young and…

16 hours ago

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…

16 hours ago

NurExone’s Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX)…

16 hours ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”…

16 hours ago